Crystal Nyitray, Encellin CEO
Encellin raises about $10M for type 1 diabetes cell replacement therapy
Encellin raised $9.9 million to join the burgeoning type 1 diabetes space with its own cell replacement therapy and first-in-human data expected next year. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
